Anthera reports Blisibimod BRIGHT-SC IgA nephropathy demonstrate positive trends
Anthera Pharmaceuticals announced positive trends from the Week 48 analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with IgA nephropathy. The effects of blisibimod versus placebo were assessed through at least the 48 week time point in all patients in the BRIGHT-SC study. December 06, 2016